



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 13 JAN 2005


WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Ans...*

Dated 17 December 2004

BEST AVAILABLE COPY

Patent Act 1977
(16)

THE PATENT OFFICE
L
16 OCT 2003

Patent
Office

16OCT03 E845094-2 002835
001/7700 0.00-0324254.2

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference	CRS/P452217		
2. Patent application number (The Patent Office will fill in this part)	0324254.2		
3. Full name, address and postcode of the or of each applicant (underline all surnames)	euphotonics Ltd Units 1 & 2 Heol Rhosyn Parc Dafen Industrial Estate Llanelli SA14 8QG United Kingdom Patents ADP number (if you know it) If the applicant is a corporate body, give the country/state of its incorporation 8734527001		
4. Title of the invention	Apparatus for Illuminating a Zone of Mammalian Skin		
5. Name of your agent (if you have one)	Urquhart-Dykes & Lord		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) Patents ADP number (if you know it)	Alexandra House 1 Alexandra Road SWANSEA SA1 5ED United Kingdom 1644005		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)	
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	Yes		

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	0
Description	10
Claim(s)	3 DL
Abstract	0
Drawing(s)	2 + 2

10. If you are also filing any of the following, state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	0
Request for preliminary examination and search (Patents Form 9/77)	1 ✓
Request for substantive examination (Patents Form 10/77)	0
Any other documents (please specify)	0

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

15 October 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Clare Salisbury

01792 474327

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

Apparatus for illuminating a zone of mammalian skin

The present invention relates to an apparatus and method for illuminating a zone of mammalian skin.

It is well known to utilize many forms of light to improve the appearance of skin. Among lighter-skinned people, for example, ultra-violet light has been used to produce a tan, and to otherwise improve general skin color and tone. In many cultures light has been used to reduce acne and other skin blemishes. Light has also been used medically to stimulate wound healing, and to treat inflammatory conditions, skin ulcers, and wrinkles.

Acne Vulgaris is a condition of the sebaceous glands which affects 80% of individuals between the ages of 11 and 30. It is not confined to these age groups however and can affect all ages from neonates to the elderly. Factors which are considered of primary significance to the condition include an increase in the production of sebum, abnormal follicular keratinisation, the presence of Propionibacterium and subsequent inflammation.

Dependant on the size, content, and depth of the inflamed acne lesion, it is defined as a papule (less than 0.5cms in diameter), nodule (elevated solid lesion > than 0.5cms) pustule (a papule what contains purulent material) or a cyst (nodule that contains fluid or semisolid matter).

Hair follicles are minute passages in the skin, which allow hairs to grow and produce sebum secretions from sebaceous glands which are housed within the hair follicle. Due to increased androgen levels or an excessive reaction by the sebaceous glands to androgen production, the sebaceous glands enlarge resulting in increased secretion of sebum which along with the keratinisation process of the epithelial cells, clog the hair follicle. Initially these blockages are microscopic then develop into whiteheads or blackheads (Comedones). Congested follicles are an ideal medium for growth of bacteria. When sebum levels are increased, the skin commensal propionibacterium ingest the clogged sebum under the skin and chemicals are produced which trigger the immune system to initiate the inflammatory changes and erythematous macules associated with Acne Vulgaris.

Inflammation is the body's response to invasion of pathogens and the redness associated with the acne lesions is the result of increased blood flow whereby the white blood cells invade bacterial cells and damage tissue and produce pus. Other fluids flood to the area and collect at the site of the inflamed tissue.

5

The approaches which are currently used for tackling Acne Vulgaris include Drug therapies (Systemic antibiotics, cortisone injections, Dianette (women only contraceptive pill, Roaccutane, Retinoids), PUVA (Psoralen and Ultra Violet light, type A), UVB Phototherapy, Dermalux (a system using a combination of red and blue light to treat acne), Peeling agents,

10

laser resurfacing, Dermabrasion and Microdermabrasion.

Known apparatus for treating acne by irradiation are disclosed, for example, in GB2356570, WO00/32272, WO02/32505 and US5549660. These apparatus are typically large and cumbersome and require a subject to visit a surgery for treatment.

15

There is a continuing need for an apparatus and method which allows administration of a low safe dose of illuminating radiation for individual need away from a doctors or cosmetic surgery.

20

The present invention provides an improved apparatus and method for illuminating a zone of mammalian skin.

According to the present invention, there is provided an apparatus for illuminating a zone of mammalian skin, the apparatus comprising:

25

- a) a light emitter;
- b) an applicator movable to direct light emitted from the light emitter to the zone of mammalian skin; and
- c) a controller controlling the duration and/or intensity of light delivered to the surface of the skin to provide a desired effect without producing significant ablation of the mammalian skin.

30

In the context of the invention, significant ablation of the skin may comprise a substantially deleterious effect upon a basal layer of skin. More particularly, "without producing significant ablation" preferably means that no more than 5% of the cells in the area of skin being irradiated die within 5 hours of the application of the light. It is even more preferable that no more than 3%, or even 1% of such cells die within the 5 hour window after such application and even more preferred that less than 1% of such cells die.

As used herein the term "light" is not limited to visible light. Also contemplated are other wavelengths of light including especially near UV and near IR. The term "light" is thus synonymous with the term "electromagnetic radiation".

The applicator is preferably adapted for removable attachment to the zone of mammalian skin. In a preferred embodiment the applicator comprises a suction cup and adhesion to the skin may be facilitated by provision of an adhesive, such as a replaceable or consumable hypo-allergenic adhesive ring. The inner surface of the suction cup is preferably of a light reflecting material. The light reflective material may be a silver or white coating or lining on the inside surface of the cup.

The apparatus preferably includes a plurality of light emitters. Preferred light emitters are light emitting diodes (LEDs) and diode lasers. The wavelength of light emitted from the light emitter is preferably substantially in the range 400nm to 1000nm, more preferably substantially in the range 400nm to 450nm and/or 570nm to 590nm, even more preferably substantially in the range 570nm to 590nm. When a plurality of light emitters are provided in accordance with a preferred embodiment of the present invention, one or more of the light emitters may emit light in a predetermined wavelength range and one or more different light emitters may emit light in a different predetermined wavelength range. For example, one or more light emitters may emit blue light (400nm to 500nm) and one or more light emitters may emit yellow light (570nm to 590nm). In a particularly preferred embodiment of the present invention, the light emitter is received in the applicator.

The controller is preferably provided in a housing which may also include a power source. The power source is preferably one or more batteries, typically one or more rechargeable batteries.

The housing is ideally a small, light, portable, pocket sized unit, typically similar in size to a personal stereo, which can be easily carried by a user, for example strapped to a belt or inserted in a pocket. The user is therefore, advantageously free to move about whilst receiving treatment from the apparatus.

5

The energy density of light directed toward the zone of mammalian skin is typically low intensity to avoid significant ablation of the mammalian skin. This provides that the apparatus is suitable for personal use away from a doctors or cosmetic surgery.

10

The controller is preferably configured to control the period of time that light is emitted from the light emitter for one treatment period. The duration of light emitted from the light emitter is preferably substantially in the range 1 minute to 1 hour, more preferably substantially in the range 20 to 40 minutes, more preferably, about 30 minutes. Desirably, the controller is configured to permit variable selection of light duration within the preferred range and/or

15

inhibit the duration of the period of light emitted above substantially 1 hour.

20

The light emitted may be pulsed or continuous wave. Pulsed energy may be preferred in order to avoid overheating of the skin whilst producing the desired effect. Also by using pulsed operation, light emitting devices (particularly LED's) may be driven harder to produce more light output. A typical LED can operate at a drive current of 50mA in continuous mode, whilst in pulsed operation, for short periods, the same diode can be pulsed at current of around 200mA. Pulsed operation will also allow more diodes to be used for a given energy source requirement, thus reducing the power requirement and prolonging the life of the battery or the like used to power the light emitters.

25

According to a further aspect, the present invention provides a method of cosmetically improving the appearance of skin, the method comprising providing apparatus according to the present invention and directing light of a predetermined wavelength toward a target area of skin in accordance with a predetermined delivery regime.

30

The method of the present invention is preferably used for the treatment of acne vulgaris.

The method according to the present invention provides a low intensity light and is therefore suitable for home use away from a doctors or cosmetic surgery without any medical intervention.

5 As hereinbefore described in connection with the apparatus of the present invention, the term "light" is not limited to visible light. Also contemplated are other wavelengths of light including especially near UV and near IR. The term "light" is thus synonymous with the term "electromagnetic radiation".

10 The period that the light is directed towards the skin is preferably substantially in the range 1 minute to 1 hour, more preferably 20 to 40 minutes, more preferably about 30 minutes.

The wavelength of light directed towards the skin surface is preferably substantially in the range 400nm to 1000nm, more preferably substantially in the range 400nm to 450nm and/or
15 570nm to 590nm, most preferably in the range 570nm to 590nm.

The light directed towards the skin surface may be pulsed or continuous wave. Pulsed energy may be preferred in order to avoid overheating of the skin whilst producing the desired effect.

20 When the apparatus or method of the present invention is used for the cosmetic treatment of a skin condition (particularly acne vulgaris), the light directed to the zone of mammalian skin typically is of a predetermined wavelength and is delivered according to a predetermined regime in order to have the desired effect at the zone of skin including a reaction leading to at least partial disabling or eradication of the cause of the skin condition.

25 A feature of the technique of the invention is that efficacy is achieved without the need of any other topically applied agent or any invasive or ablative procedure. However, it is also contemplated that the apparatus of the present invention could be used in conjunction with a topical agent (such as a retanoid) applied to the skin.

30 The radiation is typically low intensity (avoiding ablation at or below the skin surface) and typically primarily of wavelength at or about the wavelength of yellow light (570nm to 590nm)

for reasons explained in detail later. Absorption of light is through the dermal vasculature having no adverse effects on the epidermis.

Desirably, the reaction leading to at least partial removal or disabling of the cause of the skin condition is a photochemical reaction, caused by selective absorption of the predetermined wavelength light, typically by a preselected chromophore.

For Acne Vulgaris the chromophore targeted to combat the propionibacterium is porphyrin in the connective tissue. This tissue bound photosensitiser when excited from light of a certain wavelength (typically the wavelength of blue light 400nm to 450 nm and yellow light 570nm to 590nm), produces a photochemical reaction resulting in the production of singlet oxygen thereby destroying the bacterium.

Propionibacterium is averse to oxygen (anaerobic) and relies upon chemicals known as porphyrins in skin tissue. Porphyrin is usually innocuous in the absence of light. It is however photosensitive and when exposed to light of the required wavelength the photochemical reaction occurs. This results in a transition from the porphyrin's ground state to a reactive triplet state. At this level, a reaction with molecular oxygen creates singlet oxygen. Through the medium of a suitable light source, to activate the porphyrins to produce singlet oxygen, the bacterium responsible for Acne Vulgaris can be cleared in a cosmetic, pain-free, non-invasive and efficient manner.

Vasodilation and hyperaemia are integral parts of the inflammatory response, including response to infection. Therefore any inflammatory/infective focus contains a disproportionate concentration of red blood cells.

Porphyrin molecules are contained in the heme of haemoglobin so that any inflammatory or infective focus contains a concentration of natural porphyrin. Activation of this porphyrin using, for example, yellow (570nm to 590nm) light releases substances which destroys adjacent toxins such as bacteria in acne.

Similarly, any acute inflammatory condition of skin such as rosaceae will be helped although the exact toxin may be unknown.

Yellow light (570nm to 590nm) is beneficially readily absorbed by the epidermis and will generally penetrate the tissue underlying the epidermis to reach the target porphyrin.

Where the skin condition is Acne Vulgaris it is therefore preferred that the wavelength of the illuminating radiation comprises a primary wavelength or narrow wavelength band substantially in the range 570-590nm.

The photochemical interaction is typically dependent upon the number of incident photons, so the photons may be delivered in pulsed or continuous wave mode.

The target for the light has to be a material that absorbs a specific wavelength and disregards other wavelengths (chromophore). In accordance with the invention, for Acne Vulgaris, the chromophores may be porphyrin in skin tissue and oxyhaemoglobin in the dermal vasculature.

The preferred wavelength (or wavelengths) for this invention will depend upon the skin condition being treated but typically include a wavelength in the range of 400nm to 1500nm with a preferred range of 400nm to 450nm and/or 570nm to 590nm, and even more preferred range of 570 to 590nm.

The invention will now be further described in an exemplary embodiments, by way of example only, with reference to the accompanying drawings in which:

Figure 1 is a schematic view of an exemplary embodiment of the apparatus of the present invention; and

Figure 2 is a schematic view of part of the apparatus of Figure 1.

The apparatus shown in Figure 1 comprises a base unit 1 with four remote light emitters 3 (only two light emitters are shown) connected to the base unit 1 via electrical or optical leads 4.

The base unit 1 can be of any suitable size, shape, colour, material etc. It is preferred however, that the base unit 1 is a small, light, portable pocket sized unit, for example similar in size to a personal stereo. A user would therefore advantageously be able to use the apparatus at home for extended periods at their convenience, whilst moving about the home.

5

The base unit 1 houses a controller which regulates the duration and/or intensity of light emitted from the light emitters 3 to produce a desired effect without producing significant ablation of the mammalian skin.

10

A fixed resistor (not shown) may be provided to limit the current drawn by light emitters 3 and thus reduce the power required.

15

The controller may be a timer provided in the base unit 1 which can be set to provide output of light from the light emitters 3 for a predetermined period of time. By providing a low energy density of light for a long duration (typically 30 minutes) a desired effect, for example cosmetic treatment of a skin condition such as acne, typically results without producing significant ablation of the mammalian skin. The light emitted may be in a continuous wave or pulsed to improve absorption by allowing thermal relaxation periods in the treatment. The controller typically regulates the pulse width and duration according to a predetermined regime.

20

A user may desirably be able to set the controller such that the light emitted is of an energy density, duration and pulse regime according to the desired effect required and the users skin type (for example, fair or dark skinned). Alternatively, or additionally, the controller may be able to automatically set the optimal parameters typically following some input from the user, such as desired effect required and skin type. Whatever parameters are selected whether automatically or manually, the controller is suitably configured to only allow light emitted to be of a wavelength, energy density, duration and pulse regime that will not produce significant ablation of the users skin, preferably substantially no ablation. This provides that the apparatus is suitable for personal use away from a doctors or cosmetic surgery.

25

30

The base unit 1 may also house a power source. The power source can be of any known type, conventional or otherwise and is preferably one or more batteries which are ideally rechargeable.

The light emitters 3 may be light emitting diodes (LEDs) or diode lasers. Where lasers are used, the output may be monochromatic. Alternatively, or in the case where LED's are used, the radiation delivered may be "effectively" monochromatic (for example by means of appropriate filtering) or of a relatively narrow band width (typically within a band width of 15nm or less).

Preferably the light emitters 3 are LED's either in the blue, green, yellow or red spectrum, preferably the blue or yellow spectrum, most preferably the yellow spectrum. One or more of the light emitters 3 may emit light of first spectrum (for example, blue) whilst the other light emitters 3 may emit light of a second spectrum (for example, yellow) different from the first spectrum. The light emitters 3 are each connected to the base unit 1 by electrical or optical leads 4. The leads 4 have a plug 2 at one end and a suction cup 5 at the other end. The plug 2 can be removably plugged into base unit 1, so that a user can plug between one and four light emitters 3 into the base unit 1 depending on the treatment required. The light emitters 3 are each housed in the suction cup 5 attached to the end of the leads 4, as shown more clearly in Figure 2.

The inner surface of the suction cup 5 is lined with a reflective material 6, such as a silver or white lining. The reflective material acts to increase the light directed to the surface of the mammalian skin.

In use, one or more of the suction cups 5 can be attached to the surface of a users skin at any location of the body where treatment is required. For example, the suction cup 5 can be attached in the proximity of a spot to bathe the area in a controlled intensity of light for a predetermined period of time. Attachment to the skin can be facilitated by an adhesive, such as a replaceable or consumable hypoallergenic adhesive ring.

The presently disclosed apparatus and methods have numerous applications that improve the appearance of skin, that is having a desired skin effect. Where ultra-violet light is used, for example, the improvement may involve tanning. Where light is applied at 585 nm, or other wavelength that is well absorbed by the dermis, but only poorly absorbed by the epidermis or

basal layer, the improvement in skin may be in making the skin smoother. Smoother skin can be achieved, for example, through a reduction in the depth or width of a wrinkle, or through increasing collagen production under an indentation caused by acne. Another improvement may be treatment of acne, particularly acne vulgaris. Another improvement may be reduction in the growth or presence of hair, such as where the application conditions are satisfactory to kill or at least significantly damage cells structurally and/or physiologically associated with growth of hair, and particularly cortical cells including hair follicle cells, papilla cells, outer and inner root sheath cells (e.g.: Huxley's layer and Henley's layer). Still another improvement in skin can be achieved indirectly, by affecting a medical condition, such as the treatment of skin cancers. The apparatus may be used in conjunction with a photodynamic therapy (PDT) drug, typically applied to the surface of the skin where the light is directed.

Specific embodiments and applications of light therapy methods and apparatus have been disclosed. It should be apparent, however, to those skilled in the art that many more modifications besides those already described are possible without departing from the inventive concepts herein. The inventive subject matter, therefore, is not to be restricted except in the spirit of the appended claims. Moreover, in interpreting both the specification and the claims, all terms should be interpreted in the broadest possible manner consistent with the context.

Claims:

1. An apparatus for illuminating a zone of mammalian skin, the apparatus comprising:
 - a) a light emitter;
 - 5 b) an applicator movable to direct light emitted from the light emitter to the zone of mammalian skin; and
 - c) a controller controlling the duration and/or intensity of light delivered to the surface of the skin to provide a desired effect without producing significant ablation of the mammalian skin.
- 10 2. Apparatus according to claim 1, wherein, the applicator is adapted for removable attachment to the zone of mammalian skin.
3. Apparatus according to claim 2, wherein the applicator comprises a suction cup.
- 15 4. Apparatus according to claim 3, wherein adhesion of the suction cup to the skin is facilitated by provision of an adhesive, such as a replaceable or consumable hypo-allergenic adhesive ring.
- 20 5. Apparatus according to claim 3 or 4, wherein the inner surface of the suction cup is of a light reflecting material.
6. Apparatus according to any preceding claim, wherein a plurality of light emitters are included.
- 25 7. Apparatus according to any preceding claim, wherein the light emitter is a light emitting diode (LED) or diode laser.
8. Apparatus according to any preceding claim, wherein the wavelength of light emitted
30 from the light emitters is substantially in the range 400nm to 1000nm.

9. Apparatus according to any preceding claim, wherein the wavelength of light emitted from the light emitters is substantially in the range 400nm to 450nm and/or 570nm to 590nm.
- 5 10. Apparatus according to any preceding claim, wherein the wavelength of light emitted from the light emitters is substantially in the range 570nm to 590nm.
11. Apparatus according to any preceding claim, wherein the light emitter is received in the applicator.
- 10 12. Apparatus according to any preceding claim, wherein the controller is provided in a housing.
13. Apparatus according to any preceding claim, further including a power source.
- 15 14. Apparatus according to claim 13, wherein the power source is one or more batteries, preferably one or more rechargeable batteries.
- 20 15. Apparatus according to any preceding claim, wherein the controller is arranged to control the period of time that light is emitted from the light emitter for one treatment period.
- 25 16. Apparatus according to claim 15, wherein the duration of light emitted from the light emitter is substantially in the range 1 minute to 1 hour.
17. Apparatus according to claim 15, wherein the duration of light emitted from the light emitter is substantially in the range 20 to 40 minutes.
- 30 18. Apparatus according to claim 15, wherein the duration of light emitted from the light emitter is about 30 minutes.

19. Apparatus according to any of claims 15 to 18, wherein the controller is configured to permit variable selection of light duration within said range and/or inhibit the duration of the period of light emitted above a predetermined time.
- 5 20. A method of cosmetically improving the appearance of skin, the method comprising providing apparatus according to any of claims 1 to 19 and directing light of a predetermined wavelength toward a target area of skin in accordance with a predetermined delivery regime.
- 10 21. A method according to claim 20 for the treatment of acne vulgaris.
22. A method according to claim 20 or 21, wherein the period that light is directed towards the skin is substantially in the range 1 minute to 1 hour.
- 15 23. A method according to claim 22, wherein the period that light is directed towards the skin is substantially in the range 20 to 40 minutes.
24. A method according to claim 22, wherein the period that light is directed towards the skin is about 30 minutes.
- 20 25. A method according to any of claims 20 to 24, wherein the wavelength of light directed towards the skin surface is substantially in the range 400nm to 1000nm.
26. A method according to claim 25, wherein the wavelength of light directed to the skin surface is substantially in the range 400nm to 450nm and/or 570nm to 590nm.
- 25 27. A method according to claim 25, wherein the wavelength of light directed to the skin surface is substantially in the range 570nm to 590nm.
- 30 28. Apparatus substantially as herein described with reference to the accompanying drawings.

1/2




FIGURE 1

2/2




FIGURE 2

PCT/GB2004/004362



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.